Page 118 - 2020_08-Haematologica-web

F. Kramer et al.
myelofibrosis: role of growth factors. J Clin
Pathol. 1992;45(6):461-464.
9. Bock O, Loch G, Busche G, von
Wasielewski R, Schlue J, Kreipe H. Aberrant expression of platelet-derived growth factor (PDGF) and PDGF receptor- alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibro- sis. Haematologica. 2005;90(1):133-134.
10. Bedekovics J, Kiss A, Beke L, Karolyi K, Mehes G. Platelet derived growth factor receptor-beta (PDGFRbeta) expression is limited to activated stromal cells in the bone marrow and shows a strong correla- tion with the grade of myelofibrosis. Virchows Arch. 2013;463(1):57-65.
11. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimer- ic isoforms. Cytokine Growth Factor Rev. 2004;15(4):197-204.
12. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378(1):F79-113.
13. Wickenhauser C, Hillienhof A, Jungheim K, et al. Detection and quantification of trans- forming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) release by normal human megakaryocytes. Leukemia. 1995;9(2):310-315.
14. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4): 1283-1316.
15. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15(4):255-273.
16. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expres- sion (GATA-1(low) mice). Blood. 2002; 100(4):1123-1132.
17. Soderberg O, Leuchowius KJ, Gullberg M, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008;45(3):227-232.
18. Fredriksson S, Gullberg M, Jarvius J, et al. Protein detection using proximity-depen- dent DNA ligation assays. Nat Biotechnol. 2002;20(5):473-477.
19. Klinghoffer RA, Kazlauskas A. Identification of a putative Syp substrate, the PDGF beta receptor. J Biol Chem. 1995; 270(38):22208-22217.
20. Markova B, Herrlich P, Ronnstrand L, Bohmer FD. Identification of protein tyro- sine phosphatases associating with the PDGF receptor. Biochemistry. 2003; 42(9):2691-2699.
21. Persson C, Savenhed C, Bourdeau A, et al. Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phos- phorylation by T-cell protein tyrosine phosphatase. Mol Cell Biol. 2004;
24(5):2190-2201.
22. Kappert K, Paulsson J, Sparwel J, et al.
Dynamic changes in the expression of DEP- 1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J. 2007; 21(2):523-534.
23. Wiede F, Chew SH, van Vliet C, et al. Strain-dependent differences in bone devel- opment, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice. PLoS One. 2012;7(5):e36703.
24. You-Ten KE, Muise ES, Itie A, et al. Impaired bone marrow microenvironment and immune function in T cell protein tyro- sine phosphatase-deficient mice. J Exp Med. 1997;186(5):683-693.
25. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861- 1869.
26. Martinez-Calle N, Pascual M, Ordonez R, et al. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene epige- netically regulated. Haematologica. 2019; 104(8):1572-1579.
pathway and chemotaxis. Oncogene. 1999;
18(25):3696-3702.
34. Dance M, Montagner A, Salles JP, Yart A,
Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 2008; 20(3):453-459.
35. Rhee I, Davidson D, Souza CM, Vacher J, Veillette A. Macrophage fusion is con- trolled by the cytoplasmic protein tyrosine phosphatase PTP-PEST/PTPN12. Mol Cell Biol. 2013;33(12):2458-2469.
36. Rhee I, Zhong MC, Reizis B, Cheong C, Veillette A. Control of dendritic cell migra- tion, T cell-dependent immunity, and autoimmunity by protein tyrosine phos- phatase PTPN12 expressed in dendritic cells. Mol Cell Biol. 2014;34(5):888-899.
37. Pike KA, Tremblay ML. TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. Cytokine. 2016;82:52-57.
38. Tiganis T, Bennett AM, Ravichandran KS, Tonks NK. Epidermal growth factor recep- tor and the adaptor protein p52Shc are spe- cific substrates of T-cell protein tyrosine phosphatase. Mol Cell Biol. 1998; 18(3):1622-1634.
39. Bourdeau A, Trop S, Doody KM, Dumont DJ, Tremblay ML. Inhibition of T cell pro- tein tyrosine phosphatase enhances inter- leukin-18-dependent hematopoietic stem cell expansion. Stem Cells. 2013;31(2):293-
27. Verstovsek S, Mesa RA, Gotlib J, et al.
Long-term treatment with ruxolitinib for
patients with myelofibrosis: 5-year update
from the randomized, double-blind, place- bo-controlled, phase 3 COMFORT-I trial. J
Hematol Oncol. 2017;10(1):55. 304.
28. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT- II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
29. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126(13):1551- 1554.
30. Stivala S, Codilupi T, Brkic S, et al. Targeting compensatory MEK/ERK activa- tion increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;130:1596-1611.
31. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126-2133.
32. McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104(4):659-668.
33. Ronnstrand L, Arvidsson AK, Kallin A, et al. SHP-2 binds to Tyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF- induced activation of the Ras/MAP kinase
40. Panayotou G, Bax B, Gout I, et al. Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: struc- tural features and analysis of conformational changes. EMBO J. 1992;11(12):4261-4272.
41. Kashishian A, Kazlauskas A, Cooper JA. Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo. EMBO J. 1992;11(4):1373-1382.
42. Lee H, Morales LD, Slaga TJ, Kim DJ. Activation of T-cell protein-tyrosine phos- phatase suppresses keratinocyte survival and proliferation following UVB irradia- tion. J Biol Chem. 2015;290(1):13-24.
43. Lee H, Kim M, Baek M, et al. Targeted dis- ruption of TC-PTP in the proliferative com- partment augments STAT3 and AKT signal- ing and skin tumor development. Sci Rep. 2017;7:45077.
44. Wiede F, La Gruta NL, Tiganis T. PTPN2 attenuates T-cell lymphopenia-induced proliferation. Nat Commun. 2014;5:3073.
45. Patterson S, Gross J, Webster AD. DNA probes bind non-specifically to eosinophils during in situ hybridization: carbol chro- motrope blocks binding to eosinophils but does not inhibit hybridization to specific nucleotide sequences. J Virol Methods. 1989;23(2):105-109.
2094
haematologica | 2020; 105(8)